Literature DB >> 26213158

Ankle arthritis predicts polyarticular disease course and unfavourable outcome in children with juvenile idiopathic arthritis.

Anna-Clara Esbjörnsson1, Kristiina Aalto2, Eva W Broström1, Anders Fasth3, Troels Herlin4, Susan Nielsen5, Ellen Nordal6, Suvi Peltoniemi2, Marite Rygg7, Marek Zak5, Lillemor Berntson8.   

Abstract

OBJECTIVES: To evaluate the occurrence, clinical characteristics and prognostic factors associated with ankle arthritis in children with juvenile idiopathic arthritis (JIA).
METHODS: 440 children with JIA were followed for eight years in a prospective Nordic population-based cohort study. Data on remission was available for 427 of these children. Occurrence of clinically assessed ankle arthritis was analysed in relation to JIA category, clinical characteristics and remission data eight years after disease onset.
RESULTS: In 440 children with JIA, 251 (57%) experienced ankle arthritis during the first eight years of disease. Ankle arthritis was least common in the persistent oligoarticular category (25%) and most common in children with extended oligoarticular (83%) and polyarticular RF-negative (85%) JIA. Children who developed ankle arthritis during the first year of disease were younger at disease onset (median age 4.9 (IQR 2.1-8.8) vs. 6.6 (IQR 2.8-10.1) years, p<0.003) and had more cumulative affected joints at 8-year follow-up (median involved joints 10 (IQR 6-16) vs. 3 (IQR 2-9), p<0.001). The odds ratio for not achieving remission eight years after disease onset, if the ankle joint was involved during the first year of disease was 2.0 (95 % CI:1.3-3.0, p<0.001). Hind-, mid- and forefoot involvements were more common compared to patients without ankle arthritis.
CONCLUSIONS: In this Nordic population-based 8-year follow-up study, occurrence of ankle arthritis during the first year was associated with an unfavourable disease outcome. We suggest that ankle arthritis should be recognised in the assessment of prognosis and choice of treatment strategy in JIA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26213158

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis.

Authors:  Mikel Alberdi-Saugstrup; Marek Zak; Susan Nielsen; Troels Herlin; Ellen Nordal; Lillemor Berntson; Anders Fasth; Marite Rygg
Journal:  Rheumatol Int       Date:  2017-03-10       Impact factor: 2.631

Review 2.  Clinical Outcome and Long-term Remission in JIA.

Authors:  Mia Glerup; T Herlin; M Twilt
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

3.  Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization.

Authors:  Simon W M Eng; Florence A Aeschlimann; Mira van Veenendaal; Roberta A Berard; Alan M Rosenberg; Quaid Morris; Rae S M Yeung
Journal:  PLoS Med       Date:  2019-02-26       Impact factor: 11.069

4.  Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective study.

Authors:  Gordon J Hendry; Stephanie J Shoop-Worrall; Jody L Riskowski; Pamela Andrews; Eileen Baildam; Alice Chieng; Joyce Davidson; Yiannis Ioannou; Flora McErlane; Lucy R Wedderburn; Kimme Hyrich; Wendy Thomson; Martijn Steultjens
Journal:  Rheumatol Adv Pract       Date:  2018-11-24

5.  Foot and Ankle Conventional Radiography in Juvenile Idiopathic Arthritis: Does It Still Matter?

Authors:  Magdalena Posadzy; Anna Sowińska; Filip Vanhoenacker; Piotr Gietka; Ewa Żelnio; Iwona Sudoł-Szopińska
Journal:  J Belg Soc Radiol       Date:  2022-09-23       Impact factor: 1.912

6.  Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study.

Authors:  Veronika Rypdal; Ellen Dalen Arnstad; Kristiina Aalto; Lillemor Berntson; Maria Ekelund; Anders Fasth; Mia Glerup; Troels Herlin; Susan Nielsen; Suvi Peltoniemi; Marek Zak; Marite Rygg; Martin Rypdal; Ellen Nordal
Journal:  Arthritis Res Ther       Date:  2018-05-03       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.